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Abstract
Objective—Studies suggest nerve growth factor inhibitors (NGFi) relieve pain but may 
accelerate disease progression in some patients with osteoarthritis (OA). We sought cost and 
toxicity thresholds that would make NGFi a cost-effective treatment for moderate-to-severe knee 
OA.
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Design—We used the Osteoarthritis Policy (OAPol) model to estimate the cost-effectiveness of 
NGFi compared to standard of care (SOC) in OA, using Tanezumab as an example. Efficacy and 
rates of accelerated OA progression were based on published studies. We varied the price/dose 
from $200 to $1,000. We considered self-administered subcutaneous injections (no administration 
cost) vs. provider-administered IV infusion ($69-$433/dose). Strategies were defined as cost-
effective if their incremental cost-effectiveness ratio (ICER) was less than $100,000/quality-
adjusted life year (QALY). In sensitivity analyses we varied efficacy, toxicity, and costs.
Results—SOC in patients with high levels of pain led to an average discounted quality-adjusted 
life expectancy of 11.15 QALYs, a lifetime risk of TKR of 74%, and cumulative discounted direct 
medical costs of $148,700. Adding Tanezumab increased QALYs to 11.42, reduced primary TKR 
utilization to 63%, and increased costs to between $155,400 and $199,500. In the base-case 
analysis, Tanezumab at $600/dose was cost-effective when delivered outside of a hospital. At 
$1,000/dose, Tanezumab was not cost-effective in all but the most optimistic scenario. Only at 
rates of accelerated OA progression of 10% or more (10-fold higher than reported values) did 
Tanezumab decrease QALYs and fail to represent a viable option.
Conclusions—At $100,000/QALY, Tanezumab would be cost effective if priced ≤$400/dose in 
all settings except IV hospital delivery.
Keywords
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Introduction
Knee osteoarthritis (OA) is a painful debilitating disease that affects more than 9 million 
American adults1. Current medications for knee OA pain, such as non-steroidal anti-
inflammatory drugs (NSAIDs) and opioids, are limited in their long-term efficacy and 
safety2–9. Consequently, over half of patients with knee OA elect to receive total knee 
replacement surgery (TKR) within their lifetimes10. With knee OA patients estimated to 
spend an average of 13.3 years without adequate pain relief prior to TKR11, additional 
pharmacologic therapies with increased efficacy and safety could improve quality of life 
(QOL) and reduce the number of TKRs in this population12.
Nerve growth factor (NGF) represents a potential target for treatment of pain, and several 
antibodies have been developed to inhibit NGF,13, 14 the most thoroughly studied of which 
was developed by Pfizer under the trade name Tanezumab. Clinical trials documented 
impressive relief of knee OA pain, but in 2010, the FDA suspended all trials for anti-NGF 
drugs in OA due to concerns about rapidly progressing OA leading to joint replacement in 
some patients15–22. In 2012, the FDA’s Arthritis Advisory Committee (AAC) approved 
continued testing of anti-NGF drugs provided that certain safety recommendations are 
met16.
Tanezumab is a biologic drug delivered via intravenous infusion or subcutaneous injection23. 
Biologics, such as those used in rheumatoid arthritis (RA), have high costs due to the 
resources needed to produce the drugs themselves and to their mode of administration23. 
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Because OA is more prevalent than RA (12.1% vs 0.6% in the US), Tanezumab and other 
drugs in its class could conceivably be priced lower than biologics for RA1, 24.
Given the promising results surrounding the efficacy of Tanezumab, we sought to address 
several open questions: At what price might Tanezumab be cost-effective in the treatment of 
OA pain? How might the risk of accelerated OA progression affect the value of Tanezumab? 
Does Tanezumab have the potential to reduce primary and revision TKR utilization? Early 
clinical trials showed promising results regarding the attractiveness of Tanezumab for knee 
OA with some concerns about safety and no information about potential costs. Given the 
FDA’s most recent decision to continue testing of anti-NGF drugs, it makes sense at this 
point to ask what clinical outcomes, side-effect profiles, and costs might make Tanezumab a 
cost-effective option for the treatment of OA pain. Such information would provide practical 
guidance to practitioners, payers, and designers of future trials regarding performance 
benchmarks and standards of evidence for treatment and reimbursement decisions.
Methods
Analytic Overview
We used the Osteoarthritis Policy (OAPol) Model to project the clinical and economic 
implications of adding Tanezumab monotherapy to the current standard of care. Outcomes 
included lifetime medical costs, quality-adjusted life years (QALYs), incremental cost-
effectiveness ratios (ICERs), and utilization of primary and revision TKR. We determined 
the efficacy, toxicity, and cost ranges for Tanezumab that would be required to satisfy 
accepted, societal willingness to pay (WTP) thresholds. To implement trial-reported data 
into the OAPol model, we generated a sample with pain scores based on the distribution 
reported in the trial (mean pain 67.1, standard deviation 12.7)17 and then grouped the 
generated values by the pain group categories used in the OAPol model. We stratified the 
change in pain score by the initial pain groups, assuming a correlation between the initial 
and the final pain scores of 0.39, obtained from a meta-analysis comparing the pain relief 
between NSAIDs and opioids25. We considered three willingness-to-pay (WTP) thresholds 
often used in the US: $50,000/QALY, $100,000/QALY, and $150,000/QALY26–28. Results 
are presented in 2014 USD with costs and QALYs discounted at 3% per year29.
The OAPol Model
The OAPol model is a validated, state transition, Monte Carlo simulation of the natural 
history and management of knee OA30–32. The model generates cohorts of hypothetical 
subjects and assigns them initial characteristics from pre-specified distributions of age, sex, 
race/ethnicity, obesity, comorbid conditions, knee OA severity, and pain severity. The OAPol 
model accounts for the inter-relationships among key variables. For example, quality of life 
is a function of pain, obesity and comorbidities; background medical costs are based on sex, 
age and comorbidities; and pain reduction depends on baseline pain.
In the model, subjects progress through health states in 1-year intervals, during which they 
may develop comorbidities, increase body mass index (BMI), progress in OA severity, 
change in pain severity, and/or die. Five comorbidities were considered: cancer, 
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cardiovascular disease (CVD), chronic obstructive pulmonary disease, diabetes mellitus, and 
musculoskeletal conditions other than OA. Prevalence and incidence rates for these diseases 
were stratified by age, sex, race/ethnicity, and obesity. We used underlying mortality rates 
derived from the 2010 CDC life tables, accounting for increased mortality due to specific 
comorbidities33–37. The initial BMI distribution was stratified by sex and race/ethnicity with 
obesity defined as a BMI ≥ 30 kg/m2. Progression in OA severity was defined as an increase 
in Kellgren-Lawrence (K-L) radiographic grade and was stratified by sex and obesity31, 38. 
Pain severity in the OAPol model is measured on a 0–100 scale and is assigned to one of five 
pain groups. There are no well-established cut-offs for defining mild, moderate, and severe 
OA pain. Several lines of inquiry guided our effort. Kapstad et al defined thresholds between 
mild/moderate and moderate/severe at 4 and 7 out of 10 on the Body Pain Index (BPI)39. 
Since most of our data come from clinical trials that use the WOMAC Pain scale, we 
transformed the WOMAC Pain scale to a 0–100 scale with 100=worst. We did a similar 
transformation with BPI, and established thresholds of 40 and 70 for moderate and severe 
pain. To distinguish mild from moderate pain we drew upon studies of TKR efficacy 
showing WOMAC<15 reflects mild pain40. This designation has face validity in that pain 
scores between 0 and 1 (none and mild) across 5 items correspond to the 1–15 group, scores 
between 1 and 2 (mild and moderate) correspond roughly to the 16–40 group, and pain 
scores in the 3–4 (severe, extreme) range correspond to the >70 group. Downgrading by one 
group level corresponds to a clinically meaningful difference in pain41, 42. QOL decrements 
corresponding to each pain group were derived using data from the Osteoarthritis 
Initiative43, 44. Table 1 contains select cohort and treatment characteristics.
Subjects in the model undergo OA treatments that reduce pain severity, incur a cost, and may 
be associated with toxicity. Each year subjects eligible for treatment have the opportunity to 
accept or reject it. Pain reduction is drawn from published data and its magnitude depends 
on pain severity at the start of treatment. Success of treatment is defined as reduction from a 
higher to a lower pain group. In subsequent years, pain relief may end based on a defined 
probability (late failure) at which point the subject’s pain severity is set to an estimate of 
what their pain severity would have been had they not received treatment. Subjects are 
removed from non-surgical regimens when their pain severity worsens to pre-treatment 
levels. Treatment regimens carry a risk of major (e.g. myocardial infarction) and minor (e.g. 
rash) toxicity, each with an associated decrease in QOL and increase in cost. Major toxicities 
lead to regimen discontinuation and may carry a risk of death. TKR eligibility criteria of 
pain severity >40 was defined based on published literature45.
Cohort Characteristics
Initial age, sex, race/ethnicity, pain severity, and K-L distributions were derived from Lane et 
al. (2010; Table 1)17. Subjects’ age at baseline was drawn from the normal distribution with 
a mean age of 59 (standard deviation (SD) 8 years). The cohort was 59% female. Initial pain 
severity was 67 (SD 13) on the WOMAC Pain scale (0–100, with 100=worst). Cohort and 
treatment characteristics can be found in Table 131, 38.
BMI distribution of persons with OA was derived from the National Health Interview Survey 
(NHIS) 2012 and stratified by sex and race/ethnicity46. Annual medical costs unrelated to 
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OA ranged from $1,400 in young patients with at most one comorbidity to $19,100 in 
elderly patients with > 3 comorbidities. Subjects had an additional $102 in yearly costs 
associated with management of OA pain outside of specific treatment regimens34, 47–49.
Standard of Care
Subjects entered this analysis upon failure of non-invasive treatments for OA pain (NSAIDs 
and corticosteroid injections), based on inclusion criteria for past Tanezumab trials50. The 
standard of care (SOC) consisted of TKR for those whose pain severity exceeded 40 (current 
thresholds for those undergoing TKR) with K-L grades 3 or 4.
Tanezumab
Efficacy and Toxicity—Tanezumab efficacy (reduction in pain severity) was derived from 
Lane et al. (2010) and stratified by initial pain group17. Subjects experienced mean pain 
decreases in WOMAC pain scale of 13, 23 and 49 points in pain groups 3, 4, and 5, 
respectively. We estimated a late failure rate of 10% using discontinuation rates due to lack 
of efficacy for etanercept in RA51. Incidence, cost, and QOL decrease of minor toxicities 
were assumed to correspond with those found in NSAID therapy52, 53. ‘Late failure’ is 
defined as failure of a regimen that provided initial relief to provide pain relief in subsequent 
periods. The subjects remain on the regimen until the failure is ‘observed’ by a clinician. 
Subjects observed to fail (pain returned to pre-treatment levels) are removed from the 
regimen. For the base case, we assumed a late failure rate of 10% per year (analogizing from 
data on biologics for rheumatoid arthritis)51
We conducted these analyses with a validated model (OAPol) of the natural history and 
management of knee OA that has been used to examine the cost-effectiveness of opioids in 
OA, for a premarket evaluation of DMOADs, and to project lifetime costs in persons with 
knee OA11, 54, 55. We adapted the existing model to capture the essential clinical and 
economic performance attributes of Tanezumab. We added one structural feature, which 
provided the capacity to identify those who experienced rapid joint destruction, an important 
Tanezumab-related complication. We estimated a 1% chance of accelerated OA progression 
(major toxicity) in the first year and 0.5% in subsequent years based on findings from an 
independent adjudication committee18, 56. Accelerated OA progression was characterized by 
termination of Tanezumab treatment and immediate TKR. We assumed a worst-case 
scenario, and we reduced the durability and efficacy of TKR by 50% among those with joint 
destruction in order to reflect the bone destruction associated with this complication. TKR 
acceptance rates were based on data from the Multicenter Osteoarthritis Study (MOST) and 
the Osteoarthritis Initiative (OAI) and were calibrated so that all cause TKR rate in the first 
year of treatment matched those observed in large Tanezumab trials (~5%)18 For revision 
TKR, we used data from Paxton et al, since revision data were not reported due to short trial 
duration57
To assure the model output is concordant with trial-based input data, we present the results 
of the internal model validation. The model estimated the pain reduction due to Tanezumab 
at 37.8 WOMAC points, which is similar to the 33.7 (SD 19.5) point reduction seen in the 
clinical trial (an average across dosages ranging from 10 μg/kg to 100 μg/kg)17. Further, the 
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trial reported that 5% of those on Tanezumab received TKR by the end of one year with 1% 
having TKR due to joint destruction. The model derived values were 4% and 1% 
respectively.
Costs—Tanezumab costs were broken into three categories: administration, drug, and 
monitoring. Administration costs refer to the cost associated with delivery of the drug and 
varied depending on the setting (self-administered subcutaneous (SC) vs intravenous (IV); 
non-hospital vs IV outpatient) as well as the type of procedure billed (non-chemotherapeutic 
IV vs chemotheraputic IV)58, 59. While published trials of Tanezumab for knee OA have 
focused on IV delivery, Tanezumab has been delivered via SC injection in other diseases, so 
both of these modes of delivery were included in this analysis60, 61. All SC injections were 
assumed to be self-administered, while IV infusions were delivered by a healthcare provider. 
Administration costs varied from $0/injection (self-administered SC) to $433/injection. For 
the purposes of this analysis, drug cost refers to the price of one dose of Tanezumab and, in 
the absence of current pricing, was varied from $200 to $1000, consistent with costs of other 
biologic regimens for other conditions62. Based on published studies, we assumed that 
Tanezumab doses were delivered once every 8 weeks15, 17, 19. Monitoring costs for IV 
infusions were fixed at $277 and included semi-annual physician’s visits, yearly blood tests, 
and x-rays to check for OA progression every other year58. Subjects receiving self-
administered SC injections had a monitoring cost of $495, because their monitoring included 
two additional physician visits per year.
Sensitivity Analysis
We varied early efficacy and late failure rate in two-way sensitivity analyses. Recognizing 
the paucity of reliable input data for many of the parameters in our model, we chose very 
wide ranges for sensitivity analysis to identify the data values and combinations that would 
(or would not) support Tanezumab as a cost-effective option.
Across a range of costs and major toxicity rates, we examined the sensitivity of Tanezumab 
cost-effectiveness to changes in efficacy (−30%—+30% of base case) and late failure rate 
(2.5%—20%). We preformed additional sensitivity analyses in which we examined cohorts 
with a lower starting pain (35, 45).
Results
Base case analysis (high pain group)
Subjects treated with the SOC had an average discounted quality-adjusted life expectancy of 
11.15 QALYs (16.26 QALYs non-discounted). Seventy four percent of subjects initiating 
treatment with high pain in SOC underwent a primary TKR in their lifetime and 13% 
received a revision TKR. The average age at the time of primary TKR was estimated at 65.7 
years. The cumulative discounted direct medical costs were estimated at $148,700.
Adding Tanezumab increased the average life expectancy to 11.42 QALYs (16.56 QALYs 
non-discounted) and reduced primary TKR utilization to 63% (revision TKRs to 9%). 
Subjects spent an average of 6.6 years (SD 5.15) on Tanezumab. In patients who received 
Tanezumab treatment, the mean age at the time of primary TKR increased to 68.9.
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By five years, 69% of those in the standard of care strategy had severe or extreme pain, 
compared to 49% of those in the Tanezumab strategy. Further, by the end of five years, 32% 
of those in SOC strategy, and alive, had TKR, compared to 12% among those in Tanezumab 
strategy. By 10 years, the rates of TKR were 51% and 29% respectively in the SOC and 
Tenazumab groups, and the revision rates were 3.0% and 2.6% respectively. Costs ranged 
from $155,400 for self-administered Tanezumab at $200/dose to $199,500 for hospital-
administered Tanezumab at $1000/dose.
The incremental cost-effectiveness of adding Tanezumab to the SOC is presented in Figure 
2. ICERs ranged from $24,400/QALY at $200/dose when self-administered as an SC 
injection to $189,000/QALY at $1,000/dose when delivered as a chemotherapeutic IV in an 
outpatient hospital setting. At a WTP of $50,000/QALY, Tanezumab was cost-effective 
when priced at $200/dose and delivered outside of a hospital. At a WTP of $100,000/QALY, 
Tanezumab was cost-effective in all settings except hospital delivery of a chemotherapeutic 
IV when priced at $400/dose and in all non-hospital settings when priced at $600/dose. At a 
WTP of $150,000/QALY, Tanezumab was cost-effective in all settings except hospital 
chemotherapeutic IV when priced at $800/dose and in all non-hospital settings at $1,000/
dose.
Sensitivity Analyses
Initial Pain Severity
Medium pain: Subjects with an average starting pain of 45 had a QALE of 11.88 QALYs 
when treated with SOC. Sixty-three percent of subjects underwent primary TKR and 8.5% 
received revision TKR. Adding Tanezumab before primary TKR increased average QALE to 
12.06 QALY in the base case. Tanezumab decreased the number of primary and revision 
TKRs by 16% and 21%, respectively. We examined the cost-effectiveness of Tanezumab 
across the same four settings as in the base case and drug costs of $200 to $1000/dose as 
shown in the “Medium Pain” section of Figure 2. At a WTP of $50,000/QALY, Tanezumab 
was only cost-effective in subjects with a starting pain of 45 when priced at $200/dose and 
either self-administered or delivered in a non-hospital setting as a non-chemo IV. Given a 
WTP of $100,000/QALY, Tanezumab was cost-effective at a price of $400/dose when 
delivered in a non-hospital setting. At $150,000/QALY, Tanezumab was cost-effective in all 
settings except hospital chemotherapy IV at $600/dose and when self-administered at $800/
dose. It was never cost-effective at $1000/dose for subjects with starting pain of 45.
Low pain: Subjects undergoing the SOC with a baseline pain of 35 had an average QALE 
of 12.20 QALY. Sixty percent underwent primary TKR and 5.5% had revision TKR. 
Tanezumab added to the SOC increased average QALE to 12.33 QALY, reduced the number 
of primary TKRs by 14%, and decreased the number of revision TKRs by 7%. Tanezumab 
was never cost-effective in this cohort given a WTP of $50,000/QALY. At WTP of 
$100,000/QALY, Tanezumab was only cost-effective at $400/dose when self-administered. 
Given a WTP of $150,000/QALY, Tanezumab was cost-effective at $600/dose when self-
administered. Tanezumab was never cost-effective at or above $800/dose in subjects with a 
mean starting pain of 35. These results are presented in the low pain section of Figure 2.
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Efficacy—We performed two-way sensitivity analyses on efficacy and late failure of 
Tanezumab. Average QALE in sensitivity analyses ranged from 11.25 QALYs given an 
efficacy 30% lower than base case and a failure rate of 20% (vs. 10% in the base case) to 
11.72 QALYs given an efficacy 30% greater than base case and a failure rate of 2.5%. The 
proportion of subjects receiving primary and revision TKR ranged from 54.8% to 68.3% and 
7.3% to 10.5%, respectively. Figure 3 shows the reduction in surgeries when Tanezumab was 
added to SOC across these ranges of efficacy and failure.
Figure 4 depicts the sensitivity of the ICER for Tanezumab to broad, simultaneous variation 
in four important parameters. At $400/dose, Tanezumab was almost always cost-effective, 
given a WTP of $100,000/QALY; the only exceptions were scenarios involving the most 
pessimistic assumptions regarding administration costs, early efficacy and late failure rate. 
By contrast, with drug costs of $800 or more, Tanezumab was only cost-effective under the 
most optimistic assumptions.
Toxicity: rapidly progressing OA—In order to address the potential consequences of 
rapidly progressing OA, we varied the rate at which rapidly progressing OA occurred. 
Eliminating the risk of rapid OA progression increased QALE to 11.46 QALY, decreased the 
percent of subjects undergoing TKRs to 61.6% and the percent of subjects undergoing 
revision to 7.2%. When the rate of rapidly progressing OA occurrence was increased to 3%, 
utilization of primary TKR still decreased relative to SOC by 20.1% but revisions increased 
by 25.1%. The ICER for Tanezumab remained below $100,000/QALY, at $400/dose when 
delivered outside a hospital setting (Figure 5). Further increasing the rate of rapid OA 
progression to 10% decreased QALE to 11.14 QALY; under this scenario, Tanezumab was 
dominated by SOC. At rapidly progressing OA rates of 14% or more, Tanezumab also 
increased the number of primary TKRs compared with SOC.
Discussion
We conducted a premarket evaluation of Tanezumab for knee OA to provide guidance for 
future research on efficacy, toxicity, and costs that result in acceptable ICERs based on 
societal norms. Our analysis showed that Tanezumab could be cost-effective across a range 
of WTP thresholds depending on its price and the setting in which it is delivered. Adding 
Tanezumab to standard treatment options could substantially decrease utilization of TKRs. 
Tanezumab was more cost-effective in patients with more severe pain. The value of 
Tanezumab was sensitive to costs associated with its administration and rates of rapid OA 
progression.
In a recent, widely-cited article, Neumann and colleagues argue that $50,000/QALY is too 
low in the US and recommend that analysts use $50,000, $100,000, and $200,000/QALY 
instead63. They suggest that if a single threshold had to be chosen, either $100,000 or 
$150,000 would be most reasonable. Accordingly, we present analyses across WTP 
thresholds ranging from $50K/QALY to $150K/QALY.
Biologics are widely used in the treatment of RA64. Common biologic drugs for RA range in 
price from $800/dose of etanercept to nearly $4,000/dose of infliximab with higher prices in 
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drugs delivered less frequently62, 65, 66. However, our analysis suggests that Tanezumab is 
unlikely to be cost-effective treatment if priced at ≥$1,000/ dose even at a WTP of $150,000/
QALY. The cost-effectiveness of more expensive RA treatment likely reflects the fact that 
RA is a systemic disease associated with markedly decreased quality-adjusted life 
expectancy, which biologics attenuate67–69. Furthermore, TKR is a very efficacious 
treatment option for knee OA70, and society’s willingness to pay for Tanezumab may be 
limited by the existence of a very efficacious and cost-effective surgical alternative.
Tanezumab provides an additional pharmacological regimen that can delay the need for 
surgical treatment and improve QALE. In the base case, Tanezumab increased the mean age 
for primary TKR by 3.2 years. This finding is important, as younger age is associated with 
decreased implant survivorship57. Delaying the need for surgery could improve primary 
TKR outcomes and greatly reduce the need for revision TKR, a more expensive and less 
efficacious surgery58,70. Increasing the age at which patients receive primary TKR 
diminishes their lifetime risk of revision. Additionally, Tanezumab reduces the number of 
primary TKRs performed, leaving fewer TKRs to revise.
Paxton et al showed that the risk of revision among those receiving TKR earlier (i.e., in their 
fifties) is greater than among those who receive TKR later. These data suggest that activity 
level may be higher in those who are younger, leading to greater implant failure and 
utilization of revision TKR. However, interventions are generally less cost-effective in older 
than in younger persons as older persons have lower survival71.
Our analysis demonstrated that even in the case of high attrition rates, Tanezumab had the 
potential to significantly reduce primary and revision TKR utilization while improving 
QALE in a cohort of subjects with advanced OA and high pain severity.
Rapid progression of OA remains a key concern surrounding NGF inhibitors. We assumed a 
worst-case scenario approach to the impact of rapid OA progression --that patients who 
experienced this toxicity would achieve greatly reduced primary and revision TKR efficacy. 
Even under this pessimistic assumption, a 1% rate of rapid OA progression (0.5% after the 
first year of treatment) yielded a reduction in QALE of just 0.04 QALYs compared to 
Tanezumab with no risk of rapid OA progression. Accelerated OA progression had a 
significant impact on cost-effectiveness and revision TKR utilization at rates as low as 3%, 
but only at rates of rapid OA progression of 10% or more did Tanezumab cause a net 
reduction in QALE. This falls well outside the range observed in large Tanezumab trials, 
even if one attributes every joint replacement to Tanezumab treatment and considers only 
Tanezumab plus NSAID combination therapy, which carries a substantially higher risk of 
joint toxicity18. In our analyses we included the cost of radiographic monitoring to 
determine rapid progression. It is feasible that monitoring should be performed on multiple 
joints since rapid OA progression often occurred in non-index joint. The balance between 
the frequency of x-ray exposure and additional benefit of identifying rapid progression early 
are likely factors that will guide monitoring strategies. Due to low cost of radiographs, they 
are unlikely to alter cost-effectiveness results.
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Our analysis had several limitations. Since no studies have investigated long term use of 
Tanezumab, we had to estimate discontinuation rates using data from biologics drugs in RA. 
Additionally, our data on the toxicity, pain efficacy, and structural efficacy of TKR were 
derived from multiple sources.
Results of this evaluation suggest that rapid OA progression at rates observed in clinical 
trials does not lead to an overall decrease in quality-adjusted life expectancy. Therefore, 
continued research is vital to determining the appropriate role for Tanezumab in the 
treatment of OA. Tanezumab has the potential to improve QALE and decrease utilization of 
TKR, a surgery performed over 600,000 times/year in the US72; however, the cost-
effectiveness will depend heavily on how the drug is priced and appropriate selection of 
patients. These insights could help project budgetary implications upon approval of NGF 
inhibitors making society more prepared to implement these potent analgesics into general 
clinical practice.
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Figure 1. 
Model Structure
This figure provides a visual description of where Tanezumab enters the model and some 
key features of how subjects progress through the model. Conservative therapies include 
physical therapy, NSAIDs, and corticosteroid injections. Between each stage of the model, 
subjects can take acetaminophen for pain. Death can occur at any stage. Subjects may stay at 
each model phase for multiple years before progressing to the next phase.
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Figure 2. Cost-effectiveness of Adding Tanezumab by Starting Pain, Cost, and Mode of 
Administration
This figure shows the incremental cost-effectiveness ratios (ICERs) associated with adding 
Tanezumab to the standard of care. Lighter yellows indicate higher value, while darker reds 
indicate lower value. The results are stratified by starting WOMAC pain severity (0 – 100 
scale, 100 = worst) and the cost of the drug and its delivery, assuming doses are delivered 
every 8 weeks. Mean WOMAC pain severity was 67 for high pain, 45 for medium pain, and 
35 for low pain. These results all follow the base case assumption of a 1% incidence of rapid 
OA progression in the first year of treatment and 0.5% in subsequent years, where rapid OA 
progression requires immediate joint replacement with a lower than normal efficacy.
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Figure 3. Reduction in Primary and Revision TKR Utilization: Base Case Pain Analysis
This figure shows the percent reduction in primary and revision total knee replacement 
(TKR) utilization when Tanezumab is added to the standard of care given base case pain 
severity (67) and rapid OA progression rate (1%). Sensitivity analyses around base case first 
year pain relief and subsequent year late failure rate are presented, with the numerical value 
of overall base case highlighted in white. Lighter colors indicate more joint replacements 
saved than darker colors.
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Figure 4. Cost-effectiveness of Tanezumab: Sensitivity to Cost, Efficacy, and Late Failure
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This figure shows the incremental cost-effectiveness ratios (ICERs) when Tanezumab is 
added to the standard of care across a range of sensitivity analyses. Lighter yellows indicate 
higher value, while darker reds indicate lower value. The figure shows the impact of drug 
cost ($200 – $1,000 per dose), mode and setting of administration (SC vs IV, self-
administered vs non-hospital vs hospital), first year pain relief (percent difference from base 
case value), and subsequent year late failure rate (2.5% – 20% per year). These analyses all 
consider Tanezumab given to subjects with base case pain and base case incidence of rapidly 
progressing OA due to Tanezumab.
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Figure 5. Cost-effectiveness of Tanezumab: Sensitivity to Cost and Rapid OA Progression
This figure shows the sensitivity of incremental cost-effectiveness ratios to rapid OA 
progression for Tanezumab added to the standard of care. The figure shows the impact of 
drug cost ($200 – $1000 per dose), mode and setting of delivery (SC vs IV, self-administered 
vs non-hospital vs hospital), and rate of rapid OA progression, indicated as ‘toxicity’ (1%, 
3%, 5%, 10%). All other variables in this analysis were set to base case values.
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